79340795 - BRC

Information

• Trademark
• 79340795

• Source

• Serial Number

  79340795

• Registration Number

  7510051

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  February 25, 2022
  2 years ago

• Registration Date

  September 24, 2024
  2 months ago

• Transaction Date

  September 24, 2024
  2 months ago

• Status Date

  September 24, 2024
  2 months ago

• Published for Opposition Date

  July 09, 2024
  4 months ago

• Location Date

  September 23, 2024
  2 months ago

• Status Code

  700

• Current Location

  FILE REPOSITORY (FRANCONIA)

  Employee Name

  LEASER, ANDREW

• Attorney Docket Number

  571398

  Attorney Name

  Andrew D. Price & Paula E. Hopkins

• Owners

  • BicycleTx Limited

Case File Statements

• GS0051: Pharmaceuticals, for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease; none of the foregoing in the field of palliative care
• GS0441: Pharmaceutical compounding services; advisory services relating to pharmaceuticals; pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid; none of the foregoing in the field of palliative care
• GS0421: Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid; none of the foregoing in the field of palliative care

Case File Event Statements

• 9/7/2022 - 2 years ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 5/19/2022 - 2 years ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR

• 5/20/2022 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 5/24/2022 - 2 years ago

  3 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 9/10/2022 - 2 years ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 9/11/2022 - 2 years ago

  6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 9/24/2022 - 2 years ago

  7 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH

• 10/28/2022 - 2 years ago

  8 - REFUSAL PROCESSED BY MPU Type: RFRR

• 10/28/2022 - 2 years ago

  9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 11/21/2022 - 2 years ago

  10 - REFUSAL PROCESSED BY IB Type: RFNT

• 4/26/2023 - a year ago

  11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 4/26/2023 - a year ago

  12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 4/26/2023 - a year ago

  13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 5/22/2023 - a year ago

  15 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 5/22/2023 - a year ago

  14 - SUSPENSION LETTER WRITTEN Type: CNSL

• 5/22/2023 - a year ago

  16 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 10/25/2023 - a year ago

  18 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS

• 10/25/2023 - a year ago

  17 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR

• 11/12/2023 - a year ago

  19 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX

• 12/1/2023 - 12 months ago

  20 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP

• 1/8/2024 - 10 months ago

  21 - SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Type: RCCK

• 1/29/2024 - 10 months ago

  22 - FINAL REFUSAL WRITTEN Type: CNFR

• 1/29/2024 - 10 months ago

  23 - FINAL REFUSAL E-MAILED Type: GNFR

• 1/29/2024 - 10 months ago

  24 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN

• 5/29/2024 - 6 months ago

  27 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 5/29/2024 - 6 months ago

  26 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 5/29/2024 - 6 months ago

  25 - TEAS REQUEST FOR RECONSIDERATION RECEIVED Type: ERFR

• 6/1/2024 - 6 months ago

  28 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 6/19/2024 - 5 months ago

  29 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 7/9/2024 - 4 months ago

  30 - PUBLISHED FOR OPPOSITION Type: PUBO

• 7/9/2024 - 4 months ago

  31 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 9/24/2024 - 2 months ago

  32 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 9/24/2024 - 2 months ago

  33 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC